Skip to Main Content

Paper Details

Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors: Results From JAVELIN BRCA/ATM, an Open-Label, Multicenter, Phase 2b, Tumor-Agnostic Trial.
JAMA Oncology
17
2023
ATM, BRCA, BRCA-associated cancer, BRCA1, BRCA1/2, BRCA1/2- or ATM-Altered Advanced Solid Tumors, BRCA1/2-altered or ATM-altered solid tumors, BRCA1/2-associated cancer, BRCA1/2-associated tumor types, Patients, Talazoparib, cancer tumor, heritable cancer, ovarian, breast, prostate, and pancreatic cancers, participants, patient, patients, poly(ADP-ribose), poly(ADP-ribose) polymerase, programmed cell death 1, programmed cell death-ligand 1, talazoparib, tumor, uterine leiomyosarcoma, women
Author NameAffiliation
Vasilisa A RudnevaMarie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
Susan M DomchekBasser Center for BRCA , Abramson Cancer Center, University of Pennsylvania
Matthew D GalskyTisch Cancer Institute, Icahn School of Medicine at Mount Sinai
  • 1 - 3

Datasets

Release 1.2